VIF World 2024

You can share it to WeChat via the Qr code.

VIF World 2024

Enter the applet sharing event using WeChat scan.

Event Details

Vaccine Innovation Forum (VIF) World 2024 to be held in China aims to bring together experts, researchers, policymakers, and industry leaders from around the world to collaborate and advance the field of vaccine development and immunization. 

As the world faces emerging infectious threats and ongoing health challenges, it is crucial to foster international cooperation and knowledge exchange in the realm of vaccine development. This conference will serve as a platform to share cutting-edge research findings, discuss innovative vaccine technologies, address global immunization gaps, and promote equitable vaccine distribution.

Scientific Advisory Board:

VIF World 2024

VIF World 2024

VIF World 2024






VIF World 2024

VIF World 2024

Key Sessions & Topics

  • Novel Vaccine Innovation:

  • Infectious diseases

  • RNA Technology

  • Bacterial vaccines

  • Veterinary Vaccines

  • Cancer Vaccines & Immunotherapies

  • Bioprocessing & Manufacturing

  • Clinical Trial/Vaccine Safety

  • Market Access/Regulatory/International Partnership

  • Adjuvant, Formulation, and Delivery Technologies

Young Scientist Poster Session:



VIF World 2024



The future of vaccine innovation rests in the hands of the next generation of scientists, whose fresh perspectives and innovative ideas are driving breakthroughs that will shape global health. This dynamic and interactive poster session, dedicated to young scientists, provides a platform for emerging researchers to showcase their cutting-

edge work and engage in meaningful discussions within the esteemed community of the Vaccine Innovation Forum.

Pls click here for poster application


One-on-One Meeting System:



Whether you are an early-career scientist seeking mentorship, a researcher pursuing collaborative projects, or a representative of an organization exploring partnerships, this system provides the tools to shape your event experience. By matching your expertise, interests, and goals with the right counterparts, we aim to cultivate an environment where collaboration flourishes and transformative ideas take root.


Embrace this opportunity to leverage the power of personal connections in the pursuit of innovative solutions. Join us at the Vaccine Innovation Forum World and unlock the potential of one-on-one interactions that will shape the future of vaccine research, development, and deployment.

Download Event Agenda:

VIF World 2024VIF World-agenda0228.pdf

  • Adjunct Professor of Medicine, Johns Hopkins Medical School Visiting Researcher, Institute of Microbiology, Chinese Academy of Sciences President, Siber Biotechnologies LLCGeorge Siber
    George Siber
    Adjunct Professor of Medicine, Johns Hopkins Medical School Visiting Researcher, Institute of Microbiology, Chinese Academy of Sciences President, Siber Biotechnologies LLC

    Dr. Siber is an infectious disease trained physician with more than 40 years of experience in developing vaccines and antibody products. From 1996 to 2007, Dr. Siber served as Executive Vice President and Chief Scientific Officer of Wyeth Vaccines (now Pfizer) where he led the development and approval of multiple innovative childhood vaccines, including Prevenar 7 and 13, the first pneumococcal conjugate vaccines,  Rotashield, the first rotavirus diarrhea vaccine, Meningitec, the first meningococcal meningitis conjugate vaccine and FluMist, the first nasal influenza vaccine. Prior to Wyeth, Dr. Siber was Harvard Medical School Associate Professor of Medicine at Dana Farber Cancer Institute and Director of the Massachusetts Public Health Biologic Laboratories where he developed multiple vaccines and immune globulins, including Respigam, the first antibody licensed for respiratory syncytial virus. Dr. Siber most recently was a Co-founder and Board Member of Affinivax which developed a 24 valent pneumococcal vaccine and was acquired by GSK in 2022. Dr. Siber currently serves on the Scientific Advisory Boards of AdVaccine, CanSino, Clover, Everest Medicines, ILiAD, Valneva, Vaxart and Vaxxinity and has been a consultant to the NIH, EU, WHO and the Gates Foundation. Dr.Siber was member of the Board of  Trustees of the International Vaccine Institute. Dr Siber has received multiple awards including the 2016 Albert Sabin Gold Medal in vaccinology. Dr. Siber holds an MD degree from McGill University in Canada, received post‑doctoral training in Internal Medicine at Rush‑Presbyterian Hospital in Chicago and Beth Israel Hospital in Boston and training in Infectious Diseases and Vaccinology at Boston Children’s Hospital and Beth Israel Hospital, Harvard Medical School.

  • CEO, DCVMN International, IndiaRajinder Suri
    Rajinder Suri
    CEO, DCVMN International, India
    Rajinder as CEO-DCVMN International is responsible for leadership, governance, strategic vision and overall operational excellence of DCVMN. Rajinder is appointed as member GAVI’s Vaccine Investment Strategy (VIS) Steering Committee 2024, a permanent member of CEPI’s Joint Coordination Group (JCG), 2023-24, member PAVMs Talent Development WS and Regional Vaccine Manufacturing Collaborative (RVMC). To meet an un-precedented challenge posed by COVID-19, Rajinder has been actively involved in all global strategic initiatives along with COVAX partners-WHO, GAVI, CEPI, UNICEF and several other international organizations including industry associations to ensure equitable and timely access to vaccines. He has been member of several advisory expert groups including COVAX Manufacturing & Supply Chain Task Force Leadership Team, G-20 Health Working Group and Market Design and Demand Intelligence pillar of PAVM. Rajinder has over 25 years of top management experience in the industry including at the Board of Directors of the Indian subsidiary of Sanofi Pasteur and as CEO-Panacea Biotec. He has served as Member-GAVI-PPC as well as Vice-President, DCVMN Executive Committee.
  • CEO, Afrigen Biologics, South AfricaPetro Terblanche
    Petro Terblanche
    CEO, Afrigen Biologics, South Africa
    Professor Petro Terblanche has a successful track record in the strategic and operational management of technology intensive organizations. She has played a key part in the design and implementation of South Africa’s biotechnology strategy. She holds the position of Chief Executive Officer of Afrigen Biologics (Pty)Ltd based in Cape Town, South Africa. Afrigen hosts the WHO Global mRNA technology development and transfer Hub and has a mRNA Covid 19 vaccine candidate in development as part of a global program to build capacity and capabilities in LMICs to design, develop and produce mRNA vaccines. Prof Terblanche is the author of more than 200 scientific publications and conference papers in public health. Petro holds several Board positions and serves on a number of scientific advisory boards in the public health sector. She was recently acknowledged as one of the legends of science by the Academy of Sciences South Africa.
  • Professor, The Pirbright Institute, UKSimon Graham
    Simon Graham
    Professor, The Pirbright Institute, UK
    I am a veterinary immunologist with an interest in understanding mechanisms of protective immunity and its application to vaccine development. My early career focussed on parasitic diseases, I developed a natural cattle model for testing vaccines against onchocerciasis (river blindness), which provided the first proof-of-principle for vaccine-induced protection. I identified and evaluated vaccine candidate antigens from the apicomplexan parasite Theileria parva, which were designed to induce protective bovine CD8 T cell responses. More recently, my research has focussed on porcine viruses, such as classical swine fever (CSFV) and porcine reproductive and respiratory syndrome (PRRSV) viruses. I informed discussions on the use of emergency vaccination to control future CSF outbreaks by demonstrating that live attenuated CSFV prevented transmission of divergent CSFV strains after only 3 days. I showed that this rapid protection was associated with broadly reactive CD8 T cell responses, opening new avenues to develop DIVA vaccines for outbreak settings. For PRRSV, I contributed to the study of the enhanced pathogenicity of Eastern European strains, highlighting the threat these viruses pose; and contributed to vaccine development efforts through the identification of conserved T cell antigens. My current research is largely focussed on PRRSV and we are pursuing complimentary approaches to improved vaccine development. I am also leading research aimed at developing a Nipah virus vaccine for pigs and supporting COVID-19 vaccine development by using the pig as a preclinical model for assessing immunogenicity of vaccine candidates.
  • CSO, GeneOne Life Science, USAKar Muthumani
    Kar Muthumani
    CSO, GeneOne Life Science, USA
    Dr. Muthumani has been working on basic immunology and translational science, especially in vaccine and immunotherapy areas. He completed his MS and Ph.D. at the Madurai Kamaraj University and post-doctoral fellowship at the Perlman School of Medicine at the University of Pennsylvania, PA, USA, focused on viral pathogenesis, nucleic acid vaccines, and immune therapies. He has directed a translational research laboratory focusing on synthetic nucleic acid technology to develop novel vaccines and immunotherapies for emerging and reemerging infectious diseases at The Wistar Institute, PA-USA, as part of preclinical studies using small animals and non-human primates and facilitated the translation of several vaccine candidates into the human clinical trials. In addition, he was associated with, as an investigator or co-investigator, several grants, including the prestigious NIH-HVDDT program grant for HIV-1 vaccine development, a highly selective NIH directors translational grant for universal influenza vaccine development, Sponsored Research Agreement grant for studying the virus and host receptor interactions (Dengue, MAYV, POWV, and CHIKV), Defense Advanced Research Projects Agency (DARPA), WW Smith grant, and Emerson Collective Cancer Research grant regarding immunotherapeutics. Over the years, his laboratory developed, evaluated, and demonstrated the efficacy of vaccine immunogens for Human immunodeficiency virus (HIV), Chikungunya Virus (CHIKV), and Middle East Respiratory Syndrome (MERS), ZIKA, Nipah, POWV, MAYV, and SARS-CoV2 virus. Notable was that the synthetic nucleic acid vaccines MERS- Coronavirus (NCT03721718), Zika virus (NCT02887482), and SARS-CoV-2 (NCT04336410) were the first vaccines into human clinical testing. As a significant contributor to the vaccine literature, he has published 128 highly cited peer-reviewed scientific articles and book chapters, with a Google H-index of 39. In addition, the research articles appeared in scholarly journals, awarded 22 patents, and filed 25 patents (total of 47) for the work. Given his stellar scientific background and accomplishments, Dr. Muthumani is uniquely positioned to lead and tackle new challenges for emerging and reemerging diseases of public health importance or relevance.
  • Emeritus Professor, University of Massachusetts Medical School, USAShan Lu
    Shan Lu
    Emeritus Professor, University of Massachusetts Medical School, USA
  • Professor, Chonnam National University Medical School, South KoreaJoon Haeng Rhee
    Joon Haeng Rhee
    Professor, Chonnam National University Medical School, South Korea
    Dr. Joon Haeng Rhee is a graduate of Chonnam National University Medical School and received PhD from the same university. He has been working on molecular microbial pathogenesis and vaccine biology for more than 30 years. His team was the first reporter of the whole genome sequence of V. vulnificus, which became one of the most widely used standard strains in the Vibrio research field. Vaccine study was first started aiming the high mortality V. vulnificus infections. During the vaccine research, his team came across the finding that a flagellin protein of V. vulnificus has an excellent mucosal adjuvant activity in late 1990s. Now flagellin is applied to the development of effective vaccines and immunotherapeutics against diverse diseases such as cancers, allergies, and Alzheimer’s disease. He served the president of Korean Vaccine Society (KVS) from 2013 to 2015. He was elected as an ISV Fellow and serves a member of ISV Executive Board. He is currently the director of Clinical Vaccine R&D Center and Combinatorial Tumor Immunotherapy Research Center of Chonnam National University. As of November 2023, he has more than 170 papers published in peer-reviewed journals and named as an inventor on 40 patents.
  • Founder, Vaxine, AustraliaNikolai Petrovsky
    Nikolai Petrovsky
    Founder, Vaxine, Australia
    Professor Nikolai Petrovsky is a physician and vaccine researcher. He is the founder of Vaxine, an Australian biotechnology company applying novel approaches including artificial intelligence to vaccine and adjuvant development. His research has been awarded multi-million dollar contracts from the US National Institutes of Health and he has authored over 200 peer-reviewed research papers. He developed SpikoGen®, a vaccine against COVID-19 that received emergency use authorization in the Middle East in October 2021, making it the first recombinant protein vaccine against COVID-19 to achieve regulatory approval.
  • President of Global Business, SK Bioscience, South KoreaHun Kim
    Hun Kim
    President of Global Business, SK Bioscience, South Korea
  • Director of Chula Vaccine Research Center, Chulalongkorn UniversityKiat Ruxrungtham
    Kiat Ruxrungtham
    Director of Chula Vaccine Research Center, Chulalongkorn University
    Kiat Ruxrungtham, is a Professor of Medicine, Department of Medicine , Faculty of Medicine, Chulalongkorn University; and Scientific Chair of the Chula Vaccine Research Center (ChulaVRC); and Director of the Covid19 Vaccine Development Program, ChulaVRC. He is providing teaching and patient care on Allergy -Clinical Immunology and HIV Medicine at the King Chulalongkorn Memorial Hospital, Faculty of Medicine, Chulalongkorn University; and is mentoring junior researchers on HIV medicine at HIVNAT, TRCARC; vaccine and Immunology (at Chula Vaccine Research Center); and also on clinical trials. He is currently leading the Chula-Covid19 mRNA vaccine development program at ChulaVRC. Honors: He has received several awards: 2006 Outstanding Internist Award on Medical Academy, Royal College of Physicians, Thailand 2007 Outstanding Researcher Award, and the Highest Citation Award, Chulalongkorn University, Bangkok, Thailand 2011 Senior Research Scholar Award, the Thailand Research Fund 2011 Outstanding Researcher Award, National Research Council, Thailand 2015 Senior Research Scholar Award, the Thailand Research Fund 2015 Outstanding Research Award, the Thailand Research Fund 2022 A Royal Award “Contributors to the development of the country’s vaccines” from Her Royal Highness Princess Maha Chakri Sirindhorn at the 10th Vaccination Conference Publications: He has published more than 370 peer review papers on HIV, immunology, allergy, and vaccine. Contributions to national and international academics and professional organization: 1. Former President of the Allergy, Asthma and Immunology Association, Thailand (AAIAT) 2. Former President of the Thai AIDS Society (TAS) 3. Co-chair of the Co-chair of the APAACI and APAAAPARI 2018, Bangkok, Thailand 4. Co-chair of the World Allergy Congress 2023, Bangkok, Thailand 5. Chief-editor, Asian Pacific Journal of Allergy and Immunology (APJAI)
  • President of Global R&D, Clover BiopharmaceuticalsNicholas Jackson
    Nicholas Jackson
    President of Global R&D, Clover Biopharmaceuticals
  • CTO, Lemonex, KoreaDal-Hee Min
    Dal-Hee Min
    CTO, Lemonex, Korea
    Dal-Hee Min is currently co-founder & CTO of Lemonex and Professor at Seoul National University. She received her Ph.D in Chemistry from University of Chicago. After post-doctoral research at MIT, she started her academic carrier at KAIST (Korea) as an Assistant Professor in 2007 and moved to Seoul National University in 2011. Her research focuses on drug delivery systems with collective understanding on nano-surface chemistry and diverse biomedical applications of nanomaterials including mRNA vaccines and gene therapies. She received various prestigious awards including ‘KCS-Wiley Young Chemist Award’, ‘Korea L’Oreal UNESCO Fellowship Award for Women in Science’ and ‘Order of Science and Technological Merit (Do-Yak Medal)’ from Korea Government. She is actively involved in many global activities. For highlighted activities, she gave two invited talks at World Economic Forum in 2018 where she introduced DegradaBALL technology-‘Miniaturizing Biotechnology’ in sessions ‘Bio-Inspired Drug Delivery’ and ‘Harnessing Nature for Technology ‘. She also gave talks about drug delivery platform technology at mRNA health conference, PODD, JP Morgan and BIO USA. Focus Area: mRNA vaccine / gene therapy / Nanobiotechnology / Nanomedicine/ Drug Delivery / Immunotherapy
  • Executive Vice President, The Wistar Institute, USADavid Weiner
    David Weiner
    Executive Vice President, The Wistar Institute, USA

    Dr. David Weiner directs a translational research laboratory at The Wistar Institute in the area of Molecular Immunology. His group is one of the pioneering research teams in establishing the field of DNA vaccines and immunotherapies. Important reports from his lab include the first DNA vaccine studied for HIV as well as for cancer immunotherapy, the early development of DNA encoded genetic adjuvants including the particularly relevant IL-12, advances in gene optimization, and advances in electroporation (EP) technologies resulting in improved gene delivery among others. His group worked with collaborators to become the first to move DNA technology into human study. His laboratory’s work helped revitalize the field through advancement of new synthetic DNA design and modification of EP delivery approaches resulting in potent immune induction as well as the first successful Phase IIb DNA efficacy study (for HPV immunotherapy) in humans. Dr. Weiner is the recipient of numerous honors including election as a fellow to both the American Association for the Advancement of Science in 2011 and the International Society for Vaccines in 2012. He is the recipient of the NIH Director’s Transformative Research Award and received the Vaccine Industry Excellence Award for Best Academic Research Team in 2015 at the World Vaccine Congress. Weiner was honored with the prestigious Hilleman Lectureship in 2015 at the Children’s Hospital of Philadelphia Grand Rounds session and received a Stone Family Award from Abramson Cancer Center for his groundbreaking work on DNA vaccines for cancer immunotherapy. In 2019, Dr. Weiner was honored with the Scientific Achievement Award from Life Sciences PA (LSPA). Dr. Weiner returned to Wistar in 2016 from his position at The University of Pennsylvania School of Medicine as professor of Pathology and Laboratory Medicine. From 1990 to 1993, Weiner held a joint position as assistant professor of Pathology and Laboratory Medicine at The Wistar Institute and the University of Pennsylvania School of Medicine. Dr. Weiner is a co-founder of Inovio Pharmaceuticals and is a member of the Board of Directors. Dr. Weiner graduated with a B.S. in biology from SUNY at Stony Brook, N.Y., a M.S. in biology from the University of Cincinnati and a Ph.D. in developmental biology from the University of Cincinnati College of Medicine.

  • Co-Founder, WestgeneXiangrong Song
    Xiangrong Song
    Co-Founder, Westgene
    Xiangrong Song is a full professor at Sichuan University and a pharmaceutical scientist at National Key Laboratory of Biotherapy. The Song lab has developed the targeted delivery systems for gene drugs and small molecules to treat tumors, atherosclerosis, ocular diseases, infection or brain diseases. Two novel drug candidates (IND) have been approved for phase I clinical trials. She has authored more than 100 papers and is an inventor of more than 50 issued / pending patents worldwide. The technologies that Dr. Song and her colleagues have developed formed the basis for the launch of 2 biotechnology companies. The two companies are translating the aforementioned academic innovations toward commercialization and societal impact. In 2019, she was a recipient of the first prize of Science and Technology Award in Chinese National Medicine Association, for the research on immune function of Yi nationality's medicine. In 2022, she was named as the elite of science and technology in China.
  • PI, Guangzhou LaboratoryLing Chen
    Ling Chen
    PI, Guangzhou Laboratory

    Dr. Chen has been a Professor at the State Key Lab of Respiratory Disease, Guangzhou Medical University since 2013. Dr. Chen received a medical degree from Shanghai Medical College in 1984. He obtained a Ph.D. in Biochemistry and Molecular Biology from Indiana University School of Medicine. Dr. Chen completed his postdoctoral training at Dana-Farber Cancer Institute, Harvard Medical School.  From 1997-2001, Dr. Chen served as a Senior Research Fellow at Merck Research Laboratories, where he was the first inventor of Merck's Ad5-based AIDS vaccine that entered clinical trials worldwide. Dr. Chen served as Vice President of R&D for GlaxoSmithKline in 2009-2011 and as Vice President at Sanofi Pasteur in 2012. Dr. Chen has over 200 publications in infectious diseases, vaccine research, and cancer research. His current research is focused on vaccine and antibody research on adenovirus, influenza virus, and emerging viruses. Since 2020, Dr. Chen has been working on developing user-friendly intranasal vaccines and mucosal immunity.

  • Professor, Fudan UniversityHuimin Yan
    Huimin Yan
    Professor, Fudan University

    Dr. Yan graduated and earned his B.S. and Ph.D at Wuhan University. He continued to work as a teaching staff member in College of Life Sciences, Wuhan University until 1998. From 1998 to 2002, he worked with Prof. Michael E. Lamm as a Research Associate in Department of Pathology, School of Medicine, Case Western Reserve University, Cleveland, Ohio and conducted scientific research on mucosal immune functions of IgA in relation to virus infections. He returned to Wuhan University in autumn 2002 and joined in the newly established Modern Virology Research Center, College of Life Sciences, Wuhan University as an associate professor. In 2006, he moved to the Wuhan Institute of Virology, Chinese Academy of Sciences, where he was appointed as a professor and group leader to set up an independent research lab named Mucosal Immunity Research Group. His lab is a group member of the State Key Laboratory of Virology in China. He has continued his research on the mucosal IgA functions against virus infections and focused more on the intra-epithelial activities of IgA against viral non-surface and non-structure components, which helps to reveal novel anti-viral mechanisms of IgA antibodies. His lab demonstrated that measles virus (MV) non-surface protein such as matrix protein (M), non-structural protein such as phosphoprotein (P) specific IgA can interact with viral newly synthesized proteins during IgA transport through the viral infected epithelial cells, and inhibit viral replication intracellularly. He also extended his study in developing optimized recombinant flagellin as mucosal adjuvant for designing novel subunit mucosal vaccines. He obtains 3 patents issued by the United States Patent and Trademark Office and 4 patents issued by the State Intellectual Property Office of the PRC related to novel flagellin adjuvants as well as anti-caries vaccine and anti-RSV vaccine. His research is mostly funded by National Natural Science Foundation of China, the Ministry of Science and Technology of China.

  • President& General Manager, MaxvaxDexiang Chen
    Dexiang Chen
    President& General Manager, Maxvax
    Dexiang Chen, Doctor of Immunology, Mississippi State University, has been engaged in the development of vaccines and vaccine adjuvants in Pfizer, Novartis and PATH scientific and technological organizations for more than 30 years, and has presided over a number of major international public health special projects funded by international organizations, foundations and national governments. Among the more than 20 infectious disease vaccine development projects presided over and participated in, many products have been listed globally. Dr. Chen Dexiang has published more than 60 vaccine-related academic papers in world-class academic journals such as Science and Nature Medicine.
  • Professor, Xiamen UniversityShaowei Li
    Shaowei Li
    Professor, Xiamen University
    Shaowei Li Ph.D. Professor of Biochemistry and Structural Vaccinology, Xiamen University Shaowei Li is a tenured Professor of Biochemistry and Structural Vaccinology in the School of Life Sciences with a joint appointment in the School of Public Health, Xiamen University, China. He is the vaccine group leader in the National Institute of Diagnostics and Vaccine Development in infectious diseases (NIDVD), one of the academic leaders in the State Key Laboratory of Molecular Vaccinology and Diagnostics, deputy director in Fujian provincial Xiang An biomedicine laboratory. Dr. Li has inter-disciplinary research interests focusing on structural vaccinology, resulting in more than 120 peer-reviewed papers. He also has translational experience in vaccine development against infectious diseases—such as Hepatitis E vaccine and HPV vaccine, especially in aspects of immunogen design, process development and antigen characterization. Dr. Li has won two of China’s National Science and Technology Awards and been listed in the Top 20 translational researchers of 2016, ranked by Nature Biotechnology. He has served on the Product Development for Vaccines Advisory Committee (PDVAC), World Health Organization (WHO) since 2022.
  • Chief Scientific Adviser, AdvacccineBin Wang
    Bin Wang
    Chief Scientific Adviser, Advacccine
    Dr. Bin Wang is the Co-founder, Chairman of Advaccine Biotechnology Co LTD. He is also holding a distinguished professor position at the Fudan University School of Basic Medical Sciences and serves as the chairman for the Nucleic Acid Vaccines branch of the Chinese Vaccine Society. His research area is focused on the effects of therapeutic vaccination to activate T cells and the mechanism of immune regulations. He has developed novel adjuvants and recombinant vaccines, novel DNA vaccine delivery, and led to several developed vaccines being tested in human clinical trials. He received his Ph.D. from the Cincinnati Children's Hospital at the University of Cincinnati School of Medicine in 1990. He completed his postdoc training in virology and immunology at the Wistar Institute in 1992 in Philadelphia. He became an instructor and assistant professor at the University of Pennsylvania Medical School from 1993 to 1998. He was a professor and served as the Chairman of the Department of Microbiology and Immunology for six years at the College of Biological Sciences, China Agricultural University before he joined Fudan University. He was one of the very early DNA vaccine technology inventors in the 90’s and performed the first-in-human DNA vaccine trials in 1994-1996. He has been involved in several clinical trials of therapeutic vaccines against chronic HBV infections in recent years and invented a novel prophylactic RSV vaccine currently under clinical phase II testing. He has published over 160 peer-review articles and awarded 35 US and 30 Chinese patents. He serves as an editorial board member for several international journals and executive member in several professional societies.
  • BD Director, Walvax/ General Manager, Shanghai Wotai Biotechnology, ChinaAndrew Wong
    Andrew Wong
    BD Director, Walvax/ General Manager, Shanghai Wotai Biotechnology, China
    Andrew Wong is Director of Business Development at Walvax Biotechnology Co., Ltd., a public listed company in China, and the general manager of its subsidiary Shanghai Wotai Biotechnology Co., Ltd.. Andrew is responsible for managing Global Registration and Sales Department and Business Development Department at Walvax. By participating in Walvax’s efforts to become a global vaccine manufacturer, between September 2015 and March 2020, Andrew managed a three collaboration projects under a combined sum of $8.5 million funding from the Bill and Melinda Gates Foundation to support the development of bivalent, nona-valent HPV vaccines and recombinant COVID-19 vaccine for developing countries. Representing Walvax, Andrew participated in the efforts with Shanghai Zerun to secure 3 grants from CEPI to support the preclinical and clinical development of the variant recombinant COVID-19 vaccines for eventual supply to COVAX. Currently, Andrew leads his teams to work on Walvax’s global business expansion through licensing-in/out and international product registration and distribution. After academic trainings from China, Canada and United States in clinical medicine, immunology, molecular biology, and business administration with an MBA from UCLA Anderson School, Andrew Wong, MD, MBA has almost three decades’ experiences in biopharmaceutical research, business development and general management, including close to 12 years’ work experience at the world’s largest biotech company - Amgen Inc. in USA, by engaging in recombinant antibody therapeutics and anticancer small molecule drug research and development.
  • Chief Science Advisor, Africa Centres for Disease Control and Prevention, EthiopiaNicaise Ndembi
    Nicaise Ndembi
    Chief Science Advisor, Africa Centres for Disease Control and Prevention, Ethiopia
    Dr. Nicaise Ndembi is Senior strategic Advisor on Sciece and Policy to the Africa Centres for Disease Control and Prevention Director General and currently Associate Professor, Division of Epidemiology and Prevention at the Institute of Human Virology (IHV), University of Maryland School of Medicine, Baltimore, USA. Dr. Ndembi is a graduate of Kanazawa University School of Medicine, Department of Viral Infection and International Public Health, Japan and a Research Professor within the same Institution. He is a Principal Investigator on numerous grants including US National Health Institute (NIH). He has authored/co-authored more than 180 publications in peer-reviewed journals. He is the Editor-in-Chief of the Journal of Public Health in Africa (JPHIA), AIDS Research and Therapy (ARTY), and serves on various WHO and US NIH Advisory Groups.
  • President, TechImmune, USAJeffrey Ulmer
    Jeffrey Ulmer
    President, TechImmune, USA
    Jeffrey B. Ulmer, Ph.D. spent more than 30 years in vaccines R&D at Merck Research Laboratories, Chiron Corporation, Novartis and GlaxoSmithKline. His most recent leadership positions included Global Head, External R&D; Head, Preclinical R&D; and Program Head, Technical R&D. His scientific focus has been vaccine technology platforms, including DNA and mRNA vaccines, viral vectors and adjuvants. He received his Ph.D. in biochemistry from McGill University and completed his postdoctoral training in the laboratory of Nobel laureate Dr. George Palade in the Department of Cell Biology at Yale University School of Medicine. He has published over 210 scientific articles, is an inventor on 11 patents, and is a Fellow of the International Society of Vaccines where he serves as Treasurer. He is currently President, TechImmune LLC (Newport Beach, CA) and Chief Scientific Advisor, Immorna Biotherapeutics (Morrisville, NC).
  • Head, Local Production and Assistance Unit Regulation & PQ, Access to Medicines and Health Products Division,WHO, SwitzerlandJicui Dong
    Jicui Dong
    Head, Local Production and Assistance Unit Regulation & PQ, Access to Medicines and Health Products Division,WHO, Switzerland
  • Scientific Director at PATH, USAKutub Mahmood
    Kutub Mahmood
    Scientific Director at PATH, USA
    Senior biotech executive professional with expertise in viral vaccines with 30yrs experience in vaccine development. Currently at PATH, leading projects for vaccines and biologics including product development strategies for compliance with GMP and/or GLP practices as applicable for national and international regulatory framework compliance (WHO, FDA, EMA,DCGI, NMPA). Experience in national regulatory approvals and for achieving WHO pre-qualification for vaccine products. Currently project lead for polio vaccines development and scaleup for OPV and IPV related work. Current and past projects at PATH includes work related to measles-rubella, influenza, RSV, Yellow fever, live rotavirus, and SARS-CoV2 with technologies including whole virion, inactivated, vectored, live attenuated, VLPs and subunit vaccines. Holds national and international patents on VLP technology for influenza and RSV vaccines, and published in peer-reviewed journals. Presently serves as scientific advisory panel for companies and on several scientific panels for national and international vaccine meetings. Besides, serves as scientific reviewer for manuscripts submitted for publications in journals including Vaccine, Journal of Infectious Diseases, Emerging Infectious Diseases, and Human Vaccines & Therapeutics.
  • Professor, Trinity College Dublin, IrelandEd Lavelle
    Ed Lavelle
    Professor, Trinity College Dublin, Ireland
    Professor Ed Lavelle is the current Professor of Vaccine Immunology in Trinity College Dublin He was elected a member of the Royal Irish Academy (MRIA) in 2021 is currently President of ECI2024 and former President of the Irish Society for Immunology and head of the School of Biochemistry and Immunology at Trinity College Dublin, Ireland. He graduated with a BSc in Microbiology from University College Galway and a PhD in Immunology from the University of Plymouth and carried out postdoctoral research at the University of Nottingham, Rowett Research Institute, Maynooth University and Trinity College Dublin on vaccine adjuvants and immunomodulation. He was appointed at Trinity College Dublin as a lecturer in 2004, associate Professor in 2012, Professor in Immunology in 2015 and Professor of Vaccine Immunology in 2022. His research has led to the development of adjuvants suitable for inclusion in injectable and mucosal vaccines for infectious diseases and resolving their mode of action. The lab is also focused on developing therapeutic vaccines for cancer and investigating vaccine strategies that promote immunogenic cell death, leading to enhanced protective immunity.
  • VP R&D, Global Health R&D Vaccines Head and GVGH Institute, GSK, BelgiumFrancesco Berlanda Scorza
    Francesco Berlanda Scorza
    VP R&D, Global Health R&D Vaccines Head and GVGH Institute, GSK, Belgium
  • Senior Advisor, Xiamen Innovax Biotech, ChinaJames Wai Kuo Shih
    James Wai Kuo Shih
    Senior Advisor, Xiamen Innovax Biotech, China
    James W. Shih is a senior advisor at the Innovax Biotech Inc. Xiamen, China and Professor Emeritus of the School of Public Health, Xiamen University, China since 2016. For over 10 years, he was Professor of Microbiology at the National Institute of Diagnostics and Vaccine Development in infectious diseases at the Xiamen University. He retired from the National Institutes of Health, Bethesda, USA in 2006. While at NIH, he was a senior investigator and served as the Chief of Lab Study, Infectious Disease Section and Supervisor of the Transmission Transmitted Virus Lab at the Department of Transfusion Medicine, NIH Clinical Center. Prof. Shih is a microbiologist with over 40 years of experience in the biomedical field. Most of his career is associated with the development and the understanding of hepatitis viruses and their clinical implications. He has managed active research programs in viral discovery and the development and evaluation of vaccines against hepatitis B and hepatitis C. He has extensive experience in development and clinical evaluation of serological and molecular diagnostics in infectious diseases. Currently, he is engaging in developing international collaborative projects one of them is the evaluation of hepatitis E vaccine.
  • Professor, Army Medical University, ChinaHaibo Li
    Haibo Li
    Professor, Army Medical University, China
    Dr. Haibo Li is a professor in the National Engineering Research Center of Immunological Products, Department of Microbiology and Biochemical Pharmacy, Army Medical University (Third Military Medical University). He obtained his PhD in biological technology from Third Military Medical University in 2013. His current research activities focus on integrating chemical synthesis and immunology to discover novel mucosal vaccine adjuvants. He developed an original strategy to rationally design novel lipopeptides as mucosal adjuvants by mimicking the active sites of the bacterial lipoproteins. Dr. Li has published over 50 peer-reviewed papers and several books and book chapters. Now he is a council member of Chongqing Pharmacological Society.
  • Director, International Vaccine Design Center, Professor, University of Tokyo, JapanKen Ishii
    Ken Ishii
    Director, International Vaccine Design Center, Professor, University of Tokyo, Japan
  • R&D Director, Advagene, ChinaMingi Chang
    Mingi Chang
    R&D Director, Advagene, China
    • Director of Research and Development, Advagene Biopharmaceuticals Inc • Director of Biologics Division, RuenHuei Biopharmaceuticals Inc. • Research Fellow, Protein Drug Project, Development Center for Biotechnology (DCB). • Assistant Professor. Section of Immunology, Department of Medicine, Tzu Chi University
  • CSO, Reber Genetics, ChinaFrank Chang
    Frank Chang
    CSO, Reber Genetics, China

    Dr. Frank Chia-Jung Chang obtains his Ph.D. from Life Science and Institute of Genome Science department of Taiwan Yang-Ming Medical University in 2012. He received his postdoctoral training at Molecular Biology Institute of Academia Sinica (Taiwan) and worked as visiting scholar in Frances H. Arnold’s laboratory (Nobel Prize in Chemistry winner in 2018), Chemical Engineering Department of Caltech (U.S.). He joined Reber Genetics as the supervisor of R&D Division in 2014. From 2017, Frank also works for business development and strategic layout of vaccine products (technology included).


    Dr. Chang has considerable expertise in virology, microbiology, reverse vaccinology and protein engineering for industrial production. His group has successfully developed novel subunit vaccines of swine PRRSV, pan-PCV, Mycoplasma, CSFV and PEDV in Reber Genetics, furthermore, also support the study of safe vector vaccine against ASF with external partners.

  • Professor, Fudan University, ChinaShibo Jiang
    Shibo Jiang
    Professor, Fudan University, China
    Dr. Shibo Jiang is a Professor at the Shanghai Institute of Infectious Disease and Biosecurity of Fudan University, Shanghai, China. His main research interest is the development of antiviral drugs and vaccines. He has published 572 papers (total IF: 7,662, average IF: 13.4) in SCI journals such as Cell (x3), Nature (x2), Science (x2), Lancet (x4), CNS’ sister journals (x71), with total 45,327 citations and an h-index of 105. He has applied for 104 patents, 54 of which were issued, and 11 of them were licensed out with 3 classes of innovative drugs and medical products used in clinics.
  • Head, External R&D Asia Pacific, Global R&D, Sanofi Pasteur, ChinaSean Du
    Sean Du
    Head, External R&D Asia Pacific, Global R&D, Sanofi Pasteur, China
  • Lecturer, University of Sheffield, UKZoltan Kis
    Zoltan Kis
    Lecturer, University of Sheffield, UK
    Dr. Zoltán Kis is a Lecturer at the Department of Chemical and Biological Engineering at The University of Sheffield, and an Honorary Lecturer at the Department of Chemical Engineering, Imperial College London. Zoltán is leading a multidisciplinary team that is innovating and digitalising RNA vaccine and therapeutics production platform technologies. His work is addressing the challenges of producing large volumes of RNA-based vaccines and therapeutics, rapidly, at high quality and at low cost in a disease-agnostic manner. Zoltán has previously worked as a Research Associate in the Future Vaccine Manufacturing Hub at Imperial College London. He obtained his Ph.D. in Bioengineering from Imperial College London, UK, holds an M.Sc. in Applied Biotechnology and a B.Eng. in Chemical with Biochemical Engineering.
  • Co-founder and CSO, Cansino Bio, ChinaTao Zhu
    Tao Zhu
    Co-founder and CSO, Cansino Bio, China

    Dr. Tao Zhu, Ph.D. the University of Pittsburgh

    Co-founder and Chief Scientific Officer of CanSino Biologics Inc. 

    Dr. Zhu is a member of the 14th National Committee of the Chinese People's Political Consultative Conference (CPPCC) and the “Healthy China Construction” professional committee of the Chinese Peasants and Workers Democratic Party. 

    Dr. Zhu focuses on the research and development of biological products. He established multiple core technology platforms, including viral vector, polysaccharide protein conjugate vaccine, VLP recombinant vaccine and mRNA vaccine technology at CanSino. Multiple projects led by him have been selected as national “Major Science and Technology Projects for New Drug Creation” and “Major Science and Technology Projects for Infectious Diseases”. 

    Dr. Zhu has led the team to develop a series of vaccine products, of which 6 vaccine products have been registered and marketed, another 7 vaccine products are in different stages of clinical studies. He co-developed the adenovirus vector-based Ebola virus vaccine (2018), the Recombinant COVID-19 Vaccine (Convidecia, 2021), the Recombinant COVID-19 Vaccine for Inhalation(Convidecia Air, 2022), and the Recombinant COVID-19 XBB Vaccine for Inhalation(2023), with the team of Academician Chen Wei of the Institute of Bioengineering, Academy of Military Medical Sciences, all of which have been marketed. Especially, Convidecia Air is the first developed inhalation vaccine product in the global. Menhycia, which was approved in 2021, is currently the only quadrivalent meningococcal conjugate vaccine on the market in China. Dr. Zhu also holds over 50 patents and 70 publications, including 15 papers from The Lancet publishers.

  • Owner, MDW Consultant,LLC, Former SVP of R&D, Sanofi Pasteur, USAMichel De Wilde
    Michel De Wilde
    Owner, MDW Consultant,LLC, Former SVP of R&D, Sanofi Pasteur, USA

    Michel De Wilde holds a PhD in Biochemistry and has a long and successful career in Vaccine Research and Development. He currently consults for the vaccine community and is member of several Scientific Advisory Boards

    From  2001 till June 2013, Michel De Wilde was Senior Vice President, Research & Development, at sanofi pasteur where he drove the development and licensure  of a number of products.


    From 1978 till 2000, De Wilde was at SmithKline Beecham Biologicals (now GSK Vaccines) where he held positions of increasing responsibility. He played a key role in the development of several new vaccines, most notably the recombinant Hepatitis B vaccine, as well as GSK’s Malaria vaccine.


  • Associate Director, RA, MSDZhizheng Hu
    Zhizheng Hu
    Associate Director, RA, MSD
  • Research Associate, Cardiff University, UKMaria Dul
    Maria Dul
    Research Associate, Cardiff University, UK
    Maria, a chemist by training (MSc from Jagiellonian University in Krakow, Poland), completed her PhD in the School of Pharmacy and Pharmaceutical Sciences, Trinity College Dublin, working on ‘Engineering an oral delivery system for insulin’. She then moved to Cardiff University and in the last decade her research has predominantly focused on the development of innovative microneedle-based technologies for the delivery of small molecules, peptides, proteins and nucleic acids into the skin. Maria has extensive experience in the microneedle field, having used a range of microneedle prototypes in both pre-clinical and clinical projects. She is currently lead researcher in an international collaboration between key stakeholders (Microneedle Array Patch (MAP) Regulatory Working Group), which aims to advance the regulatory science of microneedle-based dosage forms by informing future guidance and developing standardized test methods for proposed MAP products.
  • Head of Process Development, Quantoom, BelgiumHela Kallel
    Hela Kallel
    Head of Process Development, Quantoom, Belgium
    Hela Kallel worked for more than 20 years at Institute Pasteur de Tunis in Tunisia; she was leading the bioprocess development lab. She worked on process improvement and on the development of vaccines using mainly animal cells and yeasts. In Jan 2020, Hela joined Univercells as a vaccine process development manager. She led the Measles and hepatitis A vaccines projects. In Jan 2022, she moved to mRNA technology and was appointed as the head of Process Development at Quantoom Biosciences. Recently She was nominated as the Head of Co-Development Projects at Univercells. Hela holds a Ph.D in biotechnology obtained at INPL in France.
  • CEO, AstriVax, BelgiumHanne Callewaer
    Hanne Callewaer
    CEO, AstriVax, Belgium

    July 2022 - current : AstriVax

    CEO and Co-founder

    July 2021 – July 2022: KU Leuven

    Entrepreneur in Residence

    June 2018 – August 2022: Oxurion

    Head Regulatory Affairs

    Business Development

    Chief Operating Officer

    March 2009 – May 2018: GSK Vaccines

    Regulatory Affairs

    Vaccine Development Leader

    Sept 2008 – Feb 2009 – Gevers Patents

    Trainee patent attorney


    Diverse experience in the life science industry exhibiting a unique capability to merge operational execution and strategic development - implementation. Global industry experience in large pharmaceutical industry as well as into smaller biotech environment. Strong experience in development of commercial, late or early stage vaccines, monoclonal antibodies, peptides and small molecules. Regulatory affairs, drug and vaccine development expertise blended with business and corporate development. Proven track record to build up and lead diverse teams. Innovative mindset, with demonstrated ability to think beyond commonly accepted boundaries, understanding well different personalities and able to perform complex and challenging tasks and capable to distil the essence from the noise.

  • CSO, Delonix Bioworks, ChinaRong Xu
    Rong Xu
    CSO, Delonix Bioworks, China

    Dr. Xu Rong has over 20 years of experience in innovative vaccine research and development and in leading vaccine R&D teams within multinational corporations. She particularly excels in preclinical vaccine research and evaluation, the development and validation of immunological methodologies, and the CMC development of vaccine products.


    Before joining Delonix, Dr. Xu held the position of Senior Vice President of Preclinical Vaccine R&D at Clover Biopharmaceuticals. Prior to that, she served as the Vice President of R&D at the Sabin Vaccine Institute in the United States, where she led the CMC development, clinical immunology assay development and validation, and non-clinical safety and efficacy studies of vaccines. Additionally, she has held several key vaccine R&D and team management roles at Profectus Biosciences, Pfizer (Wyeth), and the Seattle Biomedical Research Institute.


    In 2016, Dr. Xu was honored with the Distinguished Female Scientist Award by the Westchester Association in New York, recognizing her outstanding contributions to vaccine research and development. Dr. Xu holds a Bachelor degree in Medicine from Peking University and a Ph.D. in Immunology from the Weizmann Institute of Science in Israel.

  • Professor, Army Medical University, ChinaQuanming Zou
    Quanming Zou
    Professor, Army Medical University, China
    Quanming Zou Professor & Director National Engineering Research Center of Immunological Products, Army Medical University Dr. Quanming Zou is a professor and the director of National Engineering Research Center of Immunological Products, Army Medical University. He received his PhD degree in immunology from the Third Military Medical University and research experience in University of Hannover (GER). He serves as Member of Subjects Review Group of the Academic Degrees Committee, State Council, Member of the 12th Pharmacopoeia Commission of China, Vice director of Biochemical and Biotech Medicine Professional Committee of Chinese Pharmaceutical Association, Vice director of Vaccine Research and Development Committee of the China Association for Vaccines and Vice Chairman of Chongqing Pharmaceutical Association. Dr. Zou has engaged in researches on innovative vaccines and pathogenic mechanisms and immune response of serious resistant bacteria. Prof. Zou successfully developed the Oral Recombinant Helicobacter Pylori Vaccine, which was approved with national innovative drug license. The other novel Staphylococcus Aureus Vaccine directed by Prof. Zou, have conducted the Clinical Trial phase Ⅲ. He published over 150 papers in peer-reviewed journals such as Lancet, Gastroenterology, Gut, Nature Communication,Autophagy, J Immunol, etc., and got 32 patents granted as first inventor. He won the Second prize of National Award for Technological Invention by the State Council, Outstanding Contribution to the Science and Technology Program Award by Ministry of Science and Technology, Frist prize of Chongqing Science and Technology Invention Award, Frist prize of Chongqing Natural Science Award by Chongqing Municipal People's Government, and Merit Citation Class II.
  • Professor,IMBCAM, ChinaQihan Li
    Qihan Li
    Professor,IMBCAM, China
  • CSO, CNBG-Virogin, CanadaWilliam Jia
    William Jia
    CSO, CNBG-Virogin, Canada

    Biography :

    n  Senior Scientist, Brain Research Centre, University of British Columbia (UBC), Canada (09.1994-07.2019)

    n  Associate Professor of Neurosurgery, UBC (tenured) (09.1994-07.2019)

    n  Chief Scientific Officer, Co-founder of Virogin Biotech Ltd (05.2015- present)

    n  Chief Scientific Officer, CNBG-Virogin Biotech Ltd (2019- present)


    Dr. Jia obtained his PhD in neurobiology from University of British Columbia (1991), MSc. Psychology (1987) from Dalhousie University in Canada, and BSc. Biology from Fudan University (1982) in China. In 2015, Dr.Jia co-founded Virogin Biotech, an oncolytic virotherapy company in Canada. He is currently the chief scientific officer of Virogin and CNBG-Virogin to develop oncolytic viruses and novel vaccines.

  • Deputy Department Head, Jiangsu CDC, ChinaJingxin Li
    Jingxin Li
    Deputy Department Head, Jiangsu CDC, China

    Jingxin Li, PhD, Professor, is working at Jiangsu Provincial Center for Disease Control and Prevention. Her research is focused on vaccine clinical evaluation and immunization strategy. She has participated in a lot of epidemiology investigations and a series of clinical trials of novel vaccines, including Enterovirus type 71 vaccine, recombinant human Ad5 vectored Ebola vaccine, and Covid-19 vaccines. She has got National Natural Science Outstanding Youth Founds and Jiangsu Provincial Natural Science Funds for Distinguished youths, and hosted or participated in seven National Natural Science Founds or National Science and Technology Major Projects. She has published over 25 articles in medical journals on vaccine clinical studies, including Nature Med, Lancet Respir Med, Lancet Glob Health, etc.

  • CEO/Co-founder, Cure Bio Tech, ChinaXia Jin
    Xia Jin
    CEO/Co-founder, Cure Bio Tech, China

    Xia JIN,MD, PhD is currently an executive director and Chief Executive Officer of Immuno Cure BioTech Ltd., Hong Kong. He has hold a number of academic positions previously, including Professor of Fudan University Shanghai Public Health Clinical Center, and its Director of Vaccine & Immunology Center; Distinguished Professor of the Chinese Academy of Science(CAS), and Deputy Director of Vaccine Research Center of the Institute Pasteur of Shanghai, and Deputy Director of CAS Molecular Virology & Immunology Key Lab. Before returning China, he has been a tenure-track Associate Professor of University of Rochester. His research focuses on the immune pathogenesis of human infectious diseases such as HIV and Dengue, and pre-clinical and clinical development of vaccines against these and other human pathogens.  He has published in 140 papers in peer-reviewed journals such as Science,J. Exp. Med.,J. Clin. Inv.,Nat. Commn., J Virol., Vaccine etc..

  • Assistant Professor, University of Pennsylvania , USAMohamad-Gabriel Alameh
    Mohamad-Gabriel Alameh
    Assistant Professor, University of Pennsylvania , USA

    Dr. Alameh is an Assistant Professor at Department of Pathology and Laboratory Medicine in the University of Pennsylvania and the Children Hospital of Philadelphia (CHOP), and the co-director of the Engineered mRNA and Targeted Nanomedicine Core at the Penn RNA Institute for RNA Innovation.


    Dr. Alameh obtained his Ph.D. in Biomedical Engineering in 2017 from Polytechnique Montreal under the supervision of Dr. Michael D. Buschmann and joined the laboratory of the now Nobel laureate Dr. Drew Weissman to develop multiple nucleoside-modified messenger RNA (mRNA) vaccines, study the adjuvant effect of different ionizable lipids, and develop new lipid-based delivery systems. Dr. Alameh explored the development of a novel lipid nanoparticle (LNPs) based adjuvant platform and developed potent mRNA-based vaccines against various pathogens including Clostridium difficile.


    His research program lies at the interface of nanotechnology, material science, engineering, and medicine to develop prophylactic and therapeutic nucleic acid-based delivery platforms and optimize their manufacturing. His team studies, and model Structure-Activity Relationships of material for improved delivery systems (e.g., lipid nanoparticle therapeutics), and nucleic acid-based vaccines. Their efforts are focused on dissecting the effect of different structural and physicochemical features of the delivery systems and their components (e.g., ionizable lipids, and helper lipids in lipid nanoparticles) on the performance, stability, and toxicity of these systems before and after interaction with the biological environment to develop vaccines against enteric pathogens, in utero and postnatal gene editing, and regenerative medicine.


    Current research projects include synthesis of novel biomaterials and nanoparticles for the delivery of nucleic acid-based therapeutics (e.g., messenger RNA encoded base editors); development of mRNA-based vaccines against enteric pathogens, and the development of high-throughput screening platforms to assess material biocompatibility and toxicity.

  • CEO, Ruizhou BioJeff Zhu
    Jeff Zhu
    CEO, Ruizhou Bio
    Dr. Jeff Zhu is the founder and CEO of Shanghai Reinovax Biologics co., Ltd., a fast-growing biotech company focusing on discovery and development of innovative vaccines and other biologics. Dr. Zhu has over 20 years’ industrial experience on discovery and development of small molecules, recombinant proteins, antibodies and vaccines from the early discovery to clinical trials. He played an important role in moving multiple drug candidates from the initiation to the clinical trial stage during his 13-year tenure at Pfizer’s R & D center in San Diego. Dr. Zhu moved back to China in 2011, and served as CSO and head of the R & D at Hualan Biological Engineering Inc., and two years later worked as senior director and department head in USP, Shanghai. Dr. Zhu published earned his Ph.D. degree on biological sciences from UC, Irvine, M.S. degree on biochemistry from Georgetown university, and B.S. degree on chemistry from Tsinghua university.
  • Professor and Director  University of Karachi,  BangladashRaza Shah
    Raza Shah
    Professor and Director University of Karachi, Bangladash
    Prof. Shah is working in the area of Nanomedicines and clinical trials. He has authored six books (Elsevier) and also edited four books (Elsevier), along with 12 chapters in books and more than 460 research articles in international journals with impact factor more than 1700. He has several US patents to his credit too. He has supervised and co-supervised 34 Ph.Ds. and 44 M.S/M.Phil scholars. The research projects of Dr. Shah is funded by both National and International funding agencies. He was declared top scientist for the year 2019 by the government of Pakistan. He received the Civil award Tamgha-i-Imtiaz-2015 (Medal of Distinction) from President Islamic republic of Pakistan. Atta-ur-Rahman gold medal-2006 and Dr. Raziuddin gold medal-2015 by Pakistan Academy of Sciences. He received the Abdus Salam (Nobel Laureate) award, and was selected TWAS Young Affiliate in 2010 by The World Academy of Sciences. One of his authored books was declared best book of the year 2017 by Higher Education Commission of Pakistan. He is fellow Pakistan Academy of Sciences, fellow Islamic world academy of sciences, fellow International Union of Pure and Applied Chemistry (IUPAC), fellow the Chemical Society of Pakistan and fellow Royal College of Physicians Edinburgh. He remained a member in the panel of inspectors for Evaluation of Clinical Trial Sites from Drug Regulatory Authority of Pakistan (DRAP). He conducted 28 Phase-1 clinical-trials (BE-PK) along with 04 phase-II clinical-trials for Multinational pharma as PI. He led the vaccine (COVID-19) phase-1 clinical trial of Sinopharm company in Pakistan. He led the DRAP approved clinical trial for the treatment of COVID-19 patients with traditional Chinese medicines. Various Research Projects Sponsored by International Funding Agencies such as OPCW (Organization for the Prohibition of Chemical Weapons Netherlands), COMSTEC-ISECO (Saudi Arabia), International Foundation for Science (Sweden), Third World Academy of Sciences (Italy), DTRA (USA) and European Commission National Funding like HEC and PSF
  • CSO China, Immorna BiotherapeuticsYuanqing Liu
    Yuanqing Liu
    CSO China, Immorna Biotherapeutics
    Dr. Liu Yuanqing graduated from Shanghai Medical College of Fudan University and was a surgeon at Shanghai Zhongshan Hospital. He completed his PhD in Vrije Universiteit Brussel in Belgium and was one of the pioneers on myeloid-derived suppressors in tumors. He was previously a senior research lead at Sanofi Pasteur French headquarter, where he contributed to various vaccine projects, including cancer vaccines, vaccines against infectious diseases, pediatric vaccines, adjuvants, etc. Dr. Liu is an industry veteran with extensive experience in the development of innovative vaccines for international market. He was a member of the EU Innovative Medicine Initiative. Since 2021, he has been the Chief Scientific Officer of Immorna Biotechnology. He is based in Shanghai where Immorna has established a high-standard R&D site aiming to accelerate the development of mRNA vaccines and drugs in China.
  • Senior Scientiest, Virogin Biotech, ChinaJiang Xu
    Jiang Xu
    Senior Scientiest, Virogin Biotech, China
    Dr. Jiang Xu has served as a senior scientist at Virogin Biotech since 2021, leading the microfluidics group. Prior to this, he worked at Harvard Medical School as a postdoctoral and held a PI scientist position at Boston Molecules Inc. Dr. Xu earned his cotutelle Ph.D. in Physical Chemistry from the University of Bordeaux and Ph.D. in Chemical Engineering from the University of Waterloo. Dr. Xu is particularly passionate about the multidisciplinary research of fluid dynamics, soft matter, and biomedical engineering. He has contributed to reputable journals such as Nature Communications, Small, Physical Review Fluids, etc. Notably, his work has garnered recognition from a series of prestigious funding and awards, including Harvard Catalyst Fellowship (2021), European Erasmus Mundus Fellowship (2012, Ph.D.), NIH Rapid Acceleration of Diagnostics (RADx®) grant (2020, PI), and Shanghai Rising-Star program (2023, PI).
  • Associate Professor,Tulane University, USAElizabeth Norton
    Elizabeth Norton
    Associate Professor,Tulane University, USA
    Dr. Elizabeth B. Norton is an immunologist with 20 years of experience in evaluating immunity, vaccines, and microbial infections. The focus of her research is on immunity, including drivers of diversity and therapeutic interventions. She has a public health and research background and is an Associate Professor in the Department of Microbiology & Immunology at Tulane University in New Orleans, Louisiana, USA. Dr. Norton began her training at the Centers for Disease Control in Atlanta, GA identifying correlates of sepsis in children and assisting in field studies in African hospitals. In her doctoral and post-doctoral programs, she evaluated innate immunomodulation and mucosal delivery techniques, the latter in the laboratory of Dr. John Clements at Tulane University. A focus of her lab’s research is using mucosal adjuvants derived from heat-labile toxin (e.g., dmLT) as a strategy to improve memory responses to vaccines. This has involved adjuvanted enterotoxigenic E. coli (ETEC), polio and tuberculosis vaccines sponsored by NIH and Gates Foundation. Recently, she is also pursuing novel dmLT adjuvant combinations for oral vaccination. The Norton lab has also pioneered a derivative intranasal adjuvant called LTA1 for Klebsiella pneumoniae, opioid, and influenza vaccines and is preparing for an NIH-sponsored clinical trial with the former. Part of this research involves correlates of protection from clinical trials with these adjuvants or licensed vaccines. Since the SARS-CoV-2 pandemic, her lab is also a key part of the Tulane University Convalescent Antibody and Immunity Network (TUCAIN) evaluating cellular and memory responses to SARS-CoV-2 or other infections and vaccinations in healthy adults or special populations.
  • Chief Development Officer, Vaccines,Arcturus Therapeutics, USAIgor Smolenov
    Igor Smolenov
    Chief Development Officer, Vaccines,Arcturus Therapeutics, USA

    Igor Smolenov is the Chief Development Officer of Arcturus Therapeutics. Dr. Smolenov is an infectious disease physician dedicated to the clinical development of novel vaccines, with a proven record of accomplishment in both small biotechnology and large pharmaceutical companies. He contributed to the successful development and licensure of several innovative vaccines.

    Before joining Arcturus, Dr. Smolenov was the Executive Vice President at Clover Pharmaceuticals, where he built a robust team able to rapidly generate pivotal clinical data leading to adjuvanted COVID-19 vaccine authorization. Prior to that, Dr Smolenov served as Therapeutic Area Head, leading the development of several seasonal influenza vaccines in Seqirus (CSL), and Head of Clinical Development in Moderna Therapeutics, leading the initiation of the first clinical trials of mRNA vaccines in humans. At Novartis Vaccines, Dr. Smolenov contributed to the development and global licensure of meningococcal vaccines (Menveo, Bexsero, and MenABCWY) and the overall commercial success of the meningococcal vaccines franchise.

    Igor Smolenov graduated from Volgograd State Medical University, Russia, and holds MD, Ph.D., and Doctor of Science (Habilitation) degrees from this university. Before starting his career in the industry, he passed multiple academic steps from junior researcher to professor and head of the Allergy/immunology department of the university. He is the author of more than 50 publications in peer-reviewed journals in clinical pharmacology and vaccine development.

  • CEO, Chimigen, ChinaEric Yuenian Shi
    Eric Yuenian Shi
    CEO, Chimigen, China
    Over 35 years of experience in biomedical research and development specializing in cancer research and translational medicine. Prior to founding Chimigen Bio, Dr Shi was Co-founder/CEO of OncoVent, a clinical-stage biopharmaceutical company. OncoVent’s leading candidate, Oregovomab, is a First-in-Class cancer immunotherapeutic drug belonging to the therapeutic cancer vaccine, currently in the global phase III stage. He was Vice President of the Academy of Clinical Research and Translational Medicine in Jiangsu Province since 2011. He led 4 research projects sponsored by the China National Science Foundation and 1 cancer early diagnosis research sponsored by the National Key Technology R&D Program for the 12th Five-year Plan of China. Prior to that Dr Shi was a full Professor at Albert Einstein College of Medicine, New York, where he led 12 national research programs funded by the U.S. National Cancer Institute (NCI), U.S. Department of Defense (DOD), and American Cancer Society. Dr Shi received his doctorate degree in biochemistry in 1989 at Dartmouth Medical School. Upon graduation from Peking University School of Medicine in 1983, Dr Shi was admitted into CUSBEA (China-U.S. Biochemistry Examination Application), a very selective and competitive program leading to graduate study at Dartmouth.
  • Vice president of Chengdu Olymvax Biopharmaceuticals Inc., Head of Olymvax R&D institutionFan Fan
    Fan Fan
    Vice president of Chengdu Olymvax Biopharmaceuticals Inc., Head of Olymvax R&D institution
    Fan fan has nearly ten years experience in the biological industry and has made remarkable achievements. In 2016, she completed the in-licensing of Class I new drugs from Griffith University in Australia, which is the first aligned biological drugs project between universities in Queensland and enterprises in China. In June 2020, she was identified as the urgently needed talents and high-end talents by Chengdu High-tech Zone. She also serves as the standing committee member of Supply Chain Management Branch of China Association for Vaccines and the member of Meningitis Prevention and Control Branch of China Association for Vaccines. In September 2020, she was awarded the Advanced Individual against the epidemic by Sichuan Provincial Working Committee of Jiusan Society, and made her due contribution to the fight against the epidemic. In June 2021, she was awarded the Golden Panda "Talent Award" of Chengdu High-tech Zone.
  • CEO, InThera, South KoreaDeog-Young Choi
    Deog-Young Choi
    CEO, InThera, South Korea
    2016.05 – Present InThera Inc. CEO 2010.01 – 2015.12 LG Life Sciences, Ltd Director of Vaccine Development & Business 2000.07– 2009.12 LG Life Sciences, Ltd. R&D Center Head of Research Team 1995.09 – 1999.12 State University of New York at Stony Brook Ph.D. in Biology
  • Professor, Lanzhou Veterinary Research Institute, ChinaHuichen Guo
    Huichen Guo
    Professor, Lanzhou Veterinary Research Institute, China

    Dr. Raman Rao joined as the Chief Executive Officer at Hilleman Laboratories in February 2020. Dr. Rao has more than two decades of experience in research and development, manufacturing and commercialisation of vaccines for infectious diseases in global pharma and biotech companies. Prior to joining Hilleman Laboratories, Dr. Rao served as the Vice President of Global Product Operations with Takeda, Singapore, where he enhanced the global product portfolio while successfully leading an international team across Japan, Singapore and the United States. The teams worked in the areas of dengue, norovirus, zika, polio and other vaccines.

    Dr. Rao started his career in 2002 with Shantha Biotechnics Limited, part of Sanofi Aventis Group in India, in Clinical Research and Scientific Affairs. He holds a MD in Medical Microbiology from the Postgraduate Institute of Medical Education and Research.

    He plans to carry forward Dr. Maurice Hilleman’s legacy for providing effective solutions for global health, especially those impacting low- and middle-income countries.

  • Professor, Sun Yat-sen UniversityYongming Chen
    Yongming Chen
    Professor, Sun Yat-sen University
    Yongming Chen received his Ph.D. on polymer science in 1993 from Nankai University. From 1994 to 1998, he was Postdoctoral Researcher and later Research Assistant at the Institute of Chemistry, CAS. Then he spent the period 1998−2001 as Postdoctoral Researcher in University of Düsseldorf and University of Mainz. Since 2001, Chen was Professor at the Institute of Chemistry CAS. He moved to Sun Yat-sen University in 2013. He obtained “Distinguished Young Scholars” by National Science Foundation of China (2006). He served for Polymer, an Elsevier journal, as an Associate Editor during 2007 to 2018. He also was in Advisory Board Panel of Macromolecules and ACS Macro Letters, the ACS Publication. Professor Chen’s research interests are in the areas of biomaterials chemistry and biomaterials application in delivery of proteins and nucleic acids, specifically application in immune attenuation. He has published over 260 research articles in Science Advances, Nature Communication, Biomaterials, Nano Letters et al and obtained 10 more licenced patents.
  • Professor & Director, Jinan UniversityFeng Gao
    Feng Gao
    Professor & Director, Jinan University
    Dr. Feng Gao is a professor and director of the Institute of Molecular and Medical Virology at Jinan University. Dr. Gao has a long-standing interest in elucidating the origin, evolution and genetic variation of human and simian immunodeficiency viruses (HIV/SIV) as well as in studying gene function, pathogenesis and vaccines of HIV/SIV from the evolutionary perspective. He has published over 200 scientific research papers, including many in the top tier journals such as Cell, Nature and Science. He discovered that origin of HIV-1 in chimpanzees. He developed the consensus gene vaccine approach for induction of cross-subtype immune responses by reducing the distances between epidemic HIV-1 strains and vaccine immunogens. He also studied the coevolution of broadly neutralizing antibodies (bnAbs) and HIV-1 in the same infected host and discovered a cooperative mechanism between different bnAbs to drive maturation of the bnAb lineage. His publications have been cited over 31,000 times and his h-index is 83. Currently, his research mainly focuses on pathogenesis of viral infections, vaccines, transmission mechanisms, drug resistance, oncolytic viruses, ultra-sensitive detection and development of fetal immunity.
  • Professor, Dalian University of Technology, ChinaBingbing Sun
    Bingbing Sun
    Professor, Dalian University of Technology, China
    Dr. Bingbing Sun received B.S. and M.S. in Chemical Engineering from Dalian University of Technology (DUT), and a Ph.D. in Chemical Engineering from the University of Washington. He had his postdoctoral training at the University of California's Center for Environmental Implications of Nanotechnology (UC-CEIN) at the University of California, Los Angeles (UCLA). He starts his academic career in the School of Chemical Engineering at DUT in 2016. Currently, he is a full professor and serves as the chair of the Department of Chemical Engineering at DUT. His research interest includes vaccine adjuvants, formulation, biomaterials, nano-bio interface, and immunoengineering. He serves as earlier career researchers editorial board of BMEMat.
  • CEO, Stemirna, ChinaHangwen Li
    Hangwen Li
    CEO, Stemirna, China
    Dr. Hangwen Li holds a Ph.D from MD. Anderson Cancer Center. He was Assistant Professor at the Department of Pharmacology and Clinical Therapy of MD Anderson Cancer Center and successively received grants and awards from the US Department of Defense. He is currently a distinguished researcher of Dongfang Hospital of Tongji University, a member of the Vaccine International Cooperation Promotion Branch of the China Association For Vaccines, and a permanent member of the Nucleic Acid Vaccine Branch of the China Association For Vaccines. Dr. Li has more than 19 years of experience in the field of RNA and cancer immunotherapy. His research fields include tumor immunotherapy, RNA drugs and cancer stem cells. He has published more than 30 SCI articles and publications, and his articles have been cited for more than 3000 times. In 2021, he won the National Science and Technology System's award for Distinguished Individual in Fighting the Covid-19 Pandemic, and in 2022, he won the “Gold Gathering Award” in the Shanghai Global Talents Innovation & Entrepreneurship Competition. In 2016, Dr. Li returned to China and founded StemiRNA, which is the first company in Asia that focuses on the research and development of innovative mRNA drugs and vaccines. StemiRNA has now developed into a global leader and the first domestic platform innovative drug enterprise for mRNA vaccine and drug research and development in China. Its self-developed lipid polymer nano carrier (LPP) technology platform has been granted patents in Europe, America and other places. StemiRNA’s pipelines include mRNA vaccines and drugs for a series of infectious diseases (including COVID-19, influenza, etc.), tumors, and rare diseases.
  • VP, Innorna, ChinaZhangjing (Jim) Chen
    Zhangjing (Jim) Chen
    VP, Innorna, China
    Zhangjing Chen, VP, Clinical Science in Vaccine and Infectious disease, Innorna • Lead the development strategy and study execution for Innorna’s proprietary mRNA prophylactic vaccines since joining in 2022. • Sixteen-year journey in industry, concentrating in clinical development of anti-infective agents and prophylactic vaccines in Pfizer, Astrazeneca, Janssen and native biotech companies. • Lead or contribute to the development strategy, protocol generation, study execution, IND/CTA/BLA application, and post-marketing strategy in China for various vaccine products, including pneumococcal conjugated vaccine, COVID-19 vaccine, Respiratory Syncytial Virus vaccine, extra-intestinal pathogenic Escherichia coli vaccine. • Nine-year clinical practice in Infectious Disease in Huashan Hospital Fudan University and participated into international multi-center clinical trials or national registration clinical trials for several novel antimicrobials. • Master of Internal Medicine, Shanghai Medical College, Fudan University • Bachelor of Clinical Medicine, Shanghai Medical College, Fudan University
  • Co-founder& CSO, VisMederi, ItalyEmanuele Montomoli
    Emanuele Montomoli
    Co-founder& CSO, VisMederi, Italy
    Emanuele Montomoli was graduated in Life Sciences at University of Siena in 1997. Since November 2016 he was appointed by the Department of Molecular Medicine of University of Siena as full Professor on Public Health. Since April 2018 to 2021 he was nominated in the Executive Board of the Toscana Life Sciences Foundation. Since 2010 he he was elected as President of the Board for the “Master in vaccinology and drug development” at University of Siena. Since 2019 he was nominated in the Executive Board of Eurocine vaccines AB. In 2008 he funded VisMederi srl, an enterprise involved in laboratory activities for vaccines and antiviral drugs clinical trials. Actually, he has a role of Chief Scientific Officer in VisMederi srl. Since 1994 he has carried out epidemiological research, surveillance networks for infectious diseases and serological assays for clinical trials for vaccines. In 2015 he was appointed as scientific coordinator for a project funded by EU-IMI (Innovative Medicine Initiative) titled “Standardization and development of assays for assessment of influenza vaccine correlates of protection”. He is the author of more than 200 papers, as well as numerous abstracts and letters, published in international scientific journals.
  • Distinguished Professor, Shenzhen Institute of Advanced Technology, ChinaDiana Boraschi
    Diana Boraschi
    Distinguished Professor, Shenzhen Institute of Advanced Technology, China
    Diana Boraschi is an immunologist that built her experience in academic institutions and industrial settings in her home country (Italy) and abroad (USA, France, Austria, Korea, Brazil). She is Senior Associate Researcher at the Italian National Research Council (where she served as Institute Director) and at the Stazione Zoologica Anton Dohrn in Napoli, Italy, and Academician of the Accademia dei Fisiocritici. She is currently serving as Distinguished Professor at the Department of Pharmacology at the Shenzhen Institute of Advanced Technologies (SIAT) of the Chinese Academy of Sciences, in Shenzhen, China. She is author of over 200 peer-reviewed research articles in immunology (h-index 67, over 16000 citations), in addition to many books and book chapters, and inventor in eight patents. In 2017, she has received an honorary PhD degree by the University of Salzburg (Austria), in 2020 the High-Level Talents Program Award for Foreign Scholars, and in 2022 the Chinese Government Friendship Award. She is listed within the first 2% scientists worldwide since 2017 and in the first 1% since 2020. Her area of expertise is innate immunity and inflammation, in particular in relation to autoimmune, inflammatory and degenerative diseases, and vaccine development. Her focus on macrophages and cytokines of the IL-1 superfamily (a bioactive IL-1 domain is known as the “Boraschi loop”), and the interaction of engineered nanomaterials with immunity in humans and environmental species. She is particularly involved in higher education training activities in Europe, Asia, Africa, and South America, with a focus on poverty-related diseases.
  • Chief Scientist, Shenzhen Institute of Advanced Technology, ChinaAldo Tagliabue
    Aldo Tagliabue
    Chief Scientist, Shenzhen Institute of Advanced Technology, China
    Aldo Tagliabue has been active for more than 4 decades in research, development, management, strategic planning and establishing facilities for innovative vaccines. After a long career as experimental immunologist and as manager of large cooperation R&D projects in public-private partnerships funded by the European Commission, Aldo Tagliabue has been involved in the creation of start-up companies in the field of human vaccines, such as AchilleS Vaccines Srl, a company of the Siena Vaccine Hub (Italy), and BCGene in São Paulo (Brazil). He has recently founded Veterna Srl, to develop mRNA vaccines for veterinary infections. His scientific background is based on early experience in the public sector, including a postdoctoral period at the NCI/NIH in Bethesda, MD, USA, from 1976 to 1979, and an internship at the McMaster University in Hamilton, Ontario, Canada in 1981. This was the basis for his subsequent experiences in industry. In 1982, he joined the Sclavo Research Center in Siena (Italy) as Head of Immunology, and in 1990 he became R&D Director at the pharmaceutical company Dompé in L’Aquila (Italy). In the early 2000s, he was Deputy Director at the International Vaccine Institute in Seoul (Republic of Korea), a WHO and UN initiative, and also served as a member of the Programme/Policy Committee of the GAVI Alliance Board. In 2011, with Rino Rappuoli he created the Sclavo Vaccine Foundation, whose mission is to sustain and promote vaccines for poverty related diseases. From 2014 to 2017, he was Director General of the Regional Foundation for Biomedical Research in Milan, the funding agency of the Lombardy Region (Italy) for health sciences. He was Adjunct Professor of Immunology at the University of Bologna (Italy) from 1996 to 2006, and Adjunct Professor at the Seoul National University from 2003 to 2005. He is author of more than 120 publications in immunology and vaccinology and inventor in 10 patents. Since 2017 is Senior Associated Scientist of the Italian National Research Council. In September 2021 he moved to China, at the Shenzhen Institute for Advanced Technology, as Visiting Professor supported by Chinese Academy of Science with a President International Fellowship. Recently he was awarded with a professorship in the Yangtze River Scholar Fellowship Program for his experience in vaccinology.
  • GM/CSO, Nano Microgene, ChinaEnqi Du
    Enqi Du
    GM/CSO, Nano Microgene, China
  • Application Engineer,NanoFCM INC.Huijie Zhu
    Huijie Zhu
    Application Engineer,NanoFCM INC.
    After graduating from the University of New South Wales,she has been responsible for the application development and pre-sales technical support of nano-flow cytometry, with solid theoretical foundation and rich experience in LNP characterization.
  • Global BD Director, Aptar PharmaNektaria Karavas
    Nektaria Karavas
    Global BD Director, Aptar Pharma
    Nektaria Karavas is the Global Director of Business Development for Nasal Vaccines, Antivirals and Immuno-stimulants at Aptar Pharma. Ms. Karavas joined Aptar Pharma in 2004 and has held various commercial roles executing long-term strategy within key customer and global accounts in North America focusing on nasal drug delivery. She has contributed to multiple nasal development programs, supported commercial scale up and product launches for New Drug Applications (NDA) using an Aptar delivery device for key pharmaceutical clients across different therapeutic indications. Nektaria holds a Bachelor of Science from McGill University, Montreal, Canada
  • Vice President of Scientific Affairs, Aptar PharmaJulie D. Suman
    Julie D. Suman
    Vice President of Scientific Affairs, Aptar Pharma
    Dr. Julie D. Suman is the Vice President of Scientific Affairs for Aptar Pharma. She manages strategic scientific planning and Aptar’s Scientific Advisory Board. Dr. Suman is also the co-founder of Next Breath. She holds a B.S. in Pharmacy from Duquesne University (1996) and a Ph.D. in Pharmaceutical Sciences from the University of Maryland, Baltimore (2002). Dr. Suman serves on the External Advisory Committee of the New South Wales RNA Production and Research Network. In addition, she is a co-editor for Respiratory Drug Delivery Proceedings, an international symposium, and an an Affiliate Assistant Professor in the Department of Pharmaceutics, School of Pharmacy, Virginia Commonwealth University. Dr. Suman is the Past-Chair of the AAPS Inhalation Technology Focus Group. Dr. Suman is also a member of the Parental Drug Association Visible Particulate Taskforce. She is a licensed Maryland pharmacist. Dr. Suman has published her research in peer-reviewed journals and has been presented during podium sessions at international meetings, the FDA Topics in Bioequivalence Seminar Series and has been an invited speaker at ANVISA in Brazil. Dr. Suman’s doctoral research, which focused on the relationship between in vitro tests for nasal sprays and in vivo deposition, has been recognized for excellence by a research award presented at the International Society for Aerosols in Medicine, 2001. In 2008, Dr. Suman received an award from the Greater Baltimore Committee for Entrepreneurial Spirit.
  • Prof., Northwest A&F UniversityXiaodong Xu
    Xiaodong Xu
    Prof., Northwest A&F University
    Xu Xiaodong, currently a professor and doctoral supervisor in the School of Life Sciences of Northwest A&F University, holds a master's degree in China Agricultural University and a doctor's degree in virology from the University of Reading, UK. He is mainly engaged in the research on the gene function and molecular biological mechanism of baculovirus, the optimization of baculovirus/insect cell expression system and the application and development of protein products. More than 10 domestic invention patents and 1 PCT international invention patent have been applied. In 2019, Xu Xiaodong led a team to discover prions in viruses for the first time in the world. The relevant scientific research results were published in the internationally renowned journal Nature Communications. Xu Xiaodong, as the founder of qBac® baculovirus/insect cell protein expression system, has improved the protein yield by the level of grams per liter by knocking out many genes that affect the protein yield, inserting siRNA to inhibit the apoptosis of host cells, and fine-tuning the expression level of transcription factors.
  • CEO, Hilleman LaboratoriesRaman Rao
    Raman Rao
    CEO, Hilleman Laboratories

    Dr. Raman Rao joined as the Chief Executive Officer at Hilleman Laboratories in February 2020. Dr. Rao has more than two decades of experience in research and development, manufacturing and commercialisation of vaccines for infectious diseases in global pharma and biotech companies. Prior to joining Hilleman Laboratories, Dr. Rao served as the Vice President of Global Product Operations with Takeda, Singapore, where he enhanced the global product portfolio while successfully leading an international team across Japan, Singapore and the United States. The teams worked in the areas of dengue, norovirus, zika, polio and other vaccines.

    Dr. Rao started his career in 2002 with Shantha Biotechnics Limited, part of Sanofi Aventis Group in India, in Clinical Research and Scientific Affairs. He holds a MD in Medical Microbiology from the Postgraduate Institute of Medical Education and Research.

    He plans to carry forward Dr. Maurice Hilleman’s legacy for providing effective solutions for global health, especially those impacting low- and middle-income countries.

  • Co-founder& VP, TherarnaCaiyi Fei
    Caiyi Fei
    Co-founder& VP, Therarna
  • President, Vaccine Division, Fosun PharmaJiguo Zhang
    Jiguo Zhang
    President, Vaccine Division, Fosun Pharma
    Graduated from Peking University School of Medicine, and National School of Development at Peking University, Jeffrey Zhang has deep insights in the fields of vaccines, while having extensive experience in business management, strategy and investment. He has successively served as the head of Pfizer’s New Business Development in China, General Manager of Emerging Business Department of GSK China/Vice President of Emerging Market Strategy, as well as the Vice President of Strategy of WuXi/Vice President of WuXi Vaccine Business.
  • Professor, Tsinghua UniversityLinqi Zhang
    Linqi Zhang
    Professor, Tsinghua University
    Professor Linqi Zhang is the Director of the Comprehensive AIDS Research Center at Tsinghua University. Prof. Zhang's research focuses on HIV-1 pathogenesis and vaccine development, and has recently expanded to the field of emerging and re-emerging human viral pathogens such as SARS-CoV-1/2 and MERS-CoV. Using cutting-edge antibody and combinatorial antigen library techniques, Prof. Zhang’s research aims to characterize protective antibody immunity in infected humans and rational design of effective vaccines and therapies against the viral infection. Professor Zhang is the recipient of the National Outstanding Young Scientist Award, privileged Changjiang Professorship, and Bayer and Vanke Chair professor. He has published extensively and is among the most cited Chinese researchers in the field of microbiology and immunology. Professor Zhang has also served as a member of national expert and advisory board to the Chinese government and several international organizations on HIV/AIDS and infectious diseases,and was recently elected as a Foreign Fellow of the African Academy of Sciences.
  • Professor, Shenzhen Institute of Advanced Technology, CASFan Yang
    Fan Yang
    Professor, Shenzhen Institute of Advanced Technology, CAS
    Dr. Fan Yang, professor at the Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences. Dr. Yang earned her Ph.D. in Molecular Genetics and Computational Biology from the University of Toronto and conducted postdoctoral research at Stanford University. Her work primarily focuses on leveraging nulti-omics techniques and big data analysis algorithms to reveal the pathogenesis of diseases such as respiratory infections and autoimmune diseases, as well as the characteristics of related adaptive immune responses. Dr. Yang has published in Science, Cell, Nature Medicine, and Cell Host & Microbe and many other top articles, totaling over 4700 citations. She also acts as a peer reviewer for journals such as Genome Research, Frontiers in Oncology, PLoS Computational Biology, and Scientific Data, and served as an editor for Frontiers in Pharmacology, a Program Committee member and reviewer for ACM Special Interest Group on Computer Science Education (SIGCSE) conferences, and a committee member of the International Workshop on Computational Mathematical Models in Cancer (CMMCA).
  • Prof., Jilin University;Senior Advisor, Scientific Advisor, ProMab Forethought; Scientific Advisor, Changchun BCTHChongyang Liang
    Chongyang Liang
    Prof., Jilin University;Senior Advisor, Scientific Advisor, ProMab Forethought; Scientific Advisor, Changchun BCTH
    Professor Liang is dedicated to the development of large molecular drugs in the field of recombinant protein. He has been engaged in the research of drug action mechanism-related structural biology and physicochemical analysis for many years, leading the development of multiple innovative monoclonal antibody drugs and subunit vaccines. Through the transformation of achievements and cooperation with enterprises, he has promoted the approval of clinical trials or market launch by the US FDA and China NMPA.
  • Vice President, Suzhou HealiRNA BiotechnologyZhong Chen
    Zhong Chen
    Vice President, Suzhou HealiRNA Biotechnology
    Doctor of Pharmacy, Postdoctoral Fellow at UNC Chapel Hill, USA. During his academic career, he was awarded the title of Associated Professor. Presided over and/or participated in a number of National Natural Science Foundation projects and national Science and Technology major projects for new drug development, and participated in the successful marketing of small molecule innovative drugs. He has published 20 academic papers in international journals and authorized 10 Chinese invention patents. In the past 5 years, he has focused on the development and industrialization of nucleic acid drug delivery vectors (mRNA, siRNA) and nucleic acid medicinal chemistry, and has applied for a number of PCT patents. He has accumulated a lot of industrialization experience in nucleic acid drug project selection, delivery vector development and CMC research.
  • EX-VP, RNA Formulation&Drug Delivery, BioNtech;Prof. Johannes Gutenberg-Universität, MainzHeinrich Hass
    Heinrich Hass
    EX-VP, RNA Formulation&Drug Delivery, BioNtech;Prof. Johannes Gutenberg-Universität, Mainz

    Heinrich Haas, Department of Biopharmaceutics and Pharmaceutical Technology Johannes Gutenberg-Universität, Mainz Mainz, Germany. Ph.D. in the group of Prof. Dr. Helmuth Möhwald at Johannes-Gutenberg Universität Mainz. Researched lipid membranes and organized bio-molecular systems. In pharmaceutical industry (Munich Biotech, Medigene, BioNTech) developed different types of nanoparticle products to clinical stage. Focus on advanced approaches for nanoparticle development and control.

  • CSO, Dyadic InternationalRonen Tchelet
    Ronen Tchelet
    CSO, Dyadic International
    Ronen Tchelet, PhD: Ronen Tchelet joined Dyadic in May 2014 and has been Dyadic’s Vice President of Research and Business Development since January 2016 and later on became Dyadic’s CSO. Dr. Tchelet received his Ph.D. in Molecular Microbiology and Biotechnology from Tel Aviv University in 1993 and did his postdoctoral as an EERO fellow at the Institute of Environmental Science and Technology (EAWAG) in Switzerland. In the late 2000’s, he joined the API Division of TEVA Pharmaceutical Industries LTD., where he served as a Chief Technology Officer of Biotechnology. Dr. Tchelet leaded and directed the Research and Development Biotechnology department of TEVA’s fermentation plant in Hungary. In his work he managed and organized Biotechnology and Biosimilar projects that combined multidisciplinary areas such as development, operation, and production of API and biologics. In addition, from 2000 – 2005, Dr. Tchelet was the QA manager of COPAXONE® the flag ship TEVA¹s innovative drug. From 2007 through 2013, prior to joining Dyadic, Dr. Tchelet became the founder and the Managing Director of Codexis Laboratories Hungary kft. (CLH) and a Vice President of Codexis Inc. At CLH, he established a state-of-the-art laboratory for strain engineering and all aspects of fermentation work including process optimization and scaling up. It was during this time that Dr. Tchelet engaged with the C1 technology that was successfully developed for the Biofuel and the Bio-Industrial enzymes fields.
  • Bioprocess Services Manager,Univercells TechnologiesRimenys Carvalho
    Rimenys Carvalho
    Bioprocess Services Manager,Univercells Technologies
    Rimenys Carvalho is a Biochemical Engineering and PhD in Bioengineering. After more than 10 years working in a academia, he joined Univercells Technologies in 2020 as Bioprocess Specialist, and currently, he is working as a Bioprocess Services Manager.
  • CEO vuRoyal pharmaceutical company LLCHao Wang
    Hao Wang
    CEO vuRoyal pharmaceutical company LLC
    CEO,vuRoyal pharmaceutical company LLC(葳瑞医药), USA and China Dr. Hao Wang is currently the CEO of vuRoyal Pharmaceutical. He received his Ph.D. from MIT and MPA from Harvard University. Previously, Dr. Wang served as the vice president of the largest university-related research foundation, the Research Foundation for the State University of New York, and the chief information officer of the United States' largest comprehensive university system, the State University of New York. Hao was a partner/managing director of Accenture, a global 500 company, and served as vice president of Accenture China, leading Accenture's healthcare practice in Greater China. He had also served as deputy commissioner of the New York State Office of Mental Health. A graduate from Peking University, Dr. Wang served as an adjunct professor in several leading research universities such as Columbia University, Tsinghua University, University at Albany, and Xian Jiaotong University.
  • Director, Desert King InternationalDamian Hiley
    Damian Hiley
    Director, Desert King International
    Damian Hiley Product Manager for Vaccine Adjuvants, Desert King International, USA Since joining Desert King in 2012, Damian Hiley has played a crucial role in revolutionizing QS21 Vaccine adjuvants, leading to the pivotal launch of GMP QS21 in 2017. Beyond his substantial contributions to vaccine science, where his work underpins all commercially available vaccines with AS01 or Matrix M, Damian has spearheaded the company’s commitment to responsible forestry practices and the development of clonal plantations. His strategic oversight of the Pharmaceutical Exipient factory in Chile reflects his multifaceted expertise. Holding an MBA, Damian’s vision for sustainable innovation and leadership in global health advancements exemplifies his dedication to both environmental stewardship and medical progress.
  • Staff Scientist, Vaccine Research Center, NIHBaoshan Zhang
    Baoshan Zhang
    Staff Scientist, Vaccine Research Center, NIH
    Dr. Baoshan Zhang is a Staff Scientist at Vaccine Research Center, NIH. He has broad experiences in vaccine development with a focus on structure-based immunogen design. Dr. Zhang leads optimizing and advancing methodologies that impact the development of novel molecules and proposes investment in alternate technologies. He is one inventor of the prefusion RSV F vaccine immunogens that are licensed to several major pharmaceutical companies. His ground-breaking work on RSV prefusion F molecules is the basis for mRNA1345 RSV vaccine developed at Moderna. Dr. Zhang currently focuses on vaccine development for infectious diseases as well as for non-communicable chronic diseases.
  • Professor of Vaccinology and Translational Medicine , University of OxfordSimon Draper
    Simon Draper
    Professor of Vaccinology and Translational Medicine , University of Oxford
    Simon Draper is Professor of Vaccinology and Translational Medicine at the University of Oxford. He was based at the Jenner Institute, Nuffield Department of Medicine from 2005 until Feb 2021 when he moved his laboratory to the Department of Biochemistry. The group's clinical team are based at the University's Centre for Clinical Vaccinology and Tropical Medicine (CCVTM) on the Churchill Hospital site. The Draper Lab study vaccine-induced immunity, with a particular focus on antibody immunology and human malaria infection. A critical strength of the group is a strong dual focus on preclinical vaccine development in parallel with early-phase clinical vaccine testing and experimental medicine studies. In particular, the group's research interests span: strategies for improved vaccine antigen identification; development of improved vaccine delivery strategies; assessment of quantitative antibody correlates of protective immunity; and assessment of human vaccine-induced antibody responses to guide structure-based immunogen design and to better understand protective mechanisms of immunity.
  • Senior Scientist, Virogin BioTechKuan Zhang
    Kuan Zhang
    Senior Scientist, Virogin BioTech
    Dr. Kuan Zhang is the Senior Scientist at Virogin BioTech, specializing in anti-cancer immunotherapy and vaccine development. With a Ph.D. and postdoctoral research completed at VIDO-InterVac (Vaccine and Infectious Disease Organization) and OHRI (Ottawa Hospital Research Institute) respectively, she brings extensive expertise to her role in cancer immunotherapy research. Currently, Dr. Zhang leads the mRNA cancer therapeutic vaccines and oncolytic virus discovery pipelines in Virogin's R&D Department. She has received prestigious awards including the National High-Level University Graduate Program for Overseas Study, Mitax Accelerate Internship, Innovation Award from SK Province, and the Shanghai Key Industries Talent Special Award, among others.
  • Professor/Academician,Institute of Process Engineering, CASGuanghui Ma
    Guanghui Ma
    Professor/Academician,Institute of Process Engineering, CAS
    Guanghui Ma is a professor of the State Key Laboratory of Biochemical Engineering (SKLBCE), Institute of Process Engineering (IPE). She is an academician of CAS in China and AIMBE fellow. She is serving as Director of the State Key Laboratory of Biochemical Engineering. She received Bachelor degree from Gunma University, Master and PhD degrees from Tokyo Institute of Technology, respectively. She joined SKLBCE as a professor in 2001 and was promoted to the director in 2012. Her research interests focus on the preparation of uniform microspheres and microcapsules and their applications in biochemical engineering and biomedicine engineering, such as biochemical separation media, drug carriers, vaccine adjuvants (vaccine delivery systems), microcarriers for cell culture, and enzyme immobilization carriers. She has published over 500 papers, including Nature, Nat. Mater., Nat. Nanotechnol. Nat. Biomed. Eng., Nat. Commun., Sci. Adv., JACS, Adv. Mater., etc. She has more than 90 patents authorized, the technology and products have been commercialized in companies, and have been used in more than 500 affiliations in the world. She has received the State National Invention Award (2nd Class; 2009), the Beijing Science and Technology Award (1st Class; 2005), the Basic Research Achievement Award (1st Class prise of Science and Technology Award; 2020) of the Chemical Industry and Engineering Society of China, and Natural Science Award (1st Class; 2020) of the Chinese Society of Particuology.
  • MSAT lead, Wuxi VaccineYao Pan
    Yao Pan
    MSAT lead, Wuxi Vaccine
    Dr. Yao Pan joined Wuxi Vaccine as MSAT lead and mainly responsible for process technology transfer and process validation. Before joining Wuxi Vaccine, she worked at WuXi Biologics Germany GmbH responsible for DP MSAT and project management departments. She has more than 8 years development and manufacturing experiences with vaccines, biologics as well as molecular diagnostics. Her expertise covers early development, new technology platform establishment, project management, process technology transfer and process validation. Before industrial career, she obtained her ph. D at Universität für Bodenkultur Wien and finished her post-doc at NIOO-KNAW.
  • Chief Strategy Officer, RIGHT Foundation, KoreaHoon Sang Lee
    Hoon Sang Lee
    Chief Strategy Officer, RIGHT Foundation, Korea

    Dr. Hoon Sang Lee is a medical doctor and a global health expert, and currently the Chief Strategy Officer (CSO) of the RIGHT Foundation (Research Investment for Global Health Technology Foundation) and an adjunct professor at Yonsei University School of Public Health in Korea. Dr. Lee is also a member of Health Sector Advisory Committee of KOICA and a founding member of the Board for Korea Society of Global Health. Previously, he has worked as a health adviser for KOICA (Korea International Cooperation Agency) for bilateral health projects in various countries of Africa and Asia. Prior to KOICA, Dr. Lee worked as a medical officer at Korea CDC, managing national hepatitis B and measles immunization programme, and was involved in North Korea health programme for immunization support. Dr. Lee studied Economics and Public Policy at University of Chicago, received MD and PhD from Yonsei University School of Medicine and received MPH from Johns Hopkins School of Public Health.

  • Agenda

    Download Agenda Here:

    VIF World 2024VIF World-agenda0228.pdf

    Preparation Stage
    End of Event
    Choose ticket
    Sales End
    Vaccine company&Academia&Gov)-Due to Feb. 8, 2024
    2024-02-08 18:00
    Past Events
    Book more than 3, save RMB 2080! Available only for vaccine companies, academias&gov to apply. Tickets will include one conference pass, 2 lunch pass and access to 1-on-1 meeting system during the event.
    Solution Providers-Due to Feb. 8, 2024
    2024-02-08 18:00
    Past Events
    Book more than 3, save RMB 2080! For international solution providers. Tickets will include one conference pass, 2 lunch pass and access to 1-on-1 meeting system during the event.
    Vaccine company&Academia& Gov
    2024-03-23 00:00
    Available only for vaccine companies, academias&gov to apply. Tickets will include one conference pass, 2 lunch pass and access to 1-on-1 meeting system during the event.
    Solution Providers-After Feb.8,2024
    2024-03-23 00:00
    For international solution providers. Tickets will include one conference pass, 2 lunch pass and access to 1-on-1 meeting system during the event.

    Refund Description:No Refund

    Contact us

    Contact us